Bryan Garnier - ONWARD OPPORTUNITIES LIMITED (ONWD) ONWARD Medical: submits ARC-EX de Novo FDA application

Report

Bryan Garnier

Maria Vara

ONWARD Medical: submits ARC-EX de Novo FDA application

This morning, ONWARD announced that it had submitted its De Novo FDA application for ARC-EX in upper limb mobility for SCI patients, respecting the timelines of planned submission within H1 2024. We are pleased to see the company achieve this key milestone in bringing to market its first commercial

02/04/2024 1 EN

Underlying

ONWARD OPPORTUNITIES LIMITED

See profile

GG00BMZR1514 London Stock Exchange Guernsey

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Maria Vara

Other Reports on these Companies

Bryan Garnier

ONWARD: reports FY 2023, all focus set on ARC-EX US launch in H2 2024

ONWARD reported FY 2023 results with a cash position amounting to EUR 29.8m (FY 2022 EUR 61.8m) by YE 2023 and a net loss of EUR 36.2m (EUR 32.8m), which increase is given by the lower grant income (EUR 0.5m in 2023 vs. 2.1m in 2022) and slightly higher OpEx, mainly driven by R&D. Following the

April 25, 2024 April 25, 2024 1 EN

Bryan Garnier

ONWARD Medical: successfully raises EUR 20m, extends cash runway into mid-2025

ONWARD Medical successfully secured a capital raise of EUR 20m in total gross proceeds, extending the cash runway into mid-2025 (vs. YE 2024). While the indicative initial capital raise amount was EUR 15m, the demand from institutional investors and French retail, along with the commitment of share

March 21, 2024 March 21, 2024 1 EN

Nemetschek - SaaS momentum accelerates in Q1 2024

Nemetschek delivered solid growth in Q1 2024, with a homogenous contribution from every division. The quarter was marked by the acceleration of SaaS and subscription revenue (+68% Y/Y) and a confirmation of both short term and long-term growth objectives (+10-11% in FY2024e and >+15% in FY2025e)

April 30, 2024 April 30, 2024 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Waga Energy: Setting itself for profitable growth

Waga Energy has reported a FY 2023 EBIT loss broadly in line with expectations at EUR14.1m (vs cons. at -EUR14.2m). With 23 units in operation (0.9TWh/year), 14 under construction representing up to 1.3TWh/year of additional capacity, and a global pipeline of more than 12TWh/year, Waga Energy is on

April 30, 2024 April 30, 2024 1 EN

Aurelien Deside

Aurelien Deside

Exclusive Networks: Q1 growth dampened by high comps as expected

Yesterday evening, EXN reported Q1 2024 results in line with our estimates, suffering the effects of exceptionally high Q1 2023 comps. The group also reiterated its FY guidance and provided more details on its NEXTGEN acquisition.

April 30, 2024 April 30, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ONWARD Medical: submits ARC-EX de Novo FDA application

ONWARD: reports FY 2023, all focus set on ARC-EX US launch in H2 2024

ONWARD Medical: successfully raises EUR 20m, extends cash runway into mid-2025

Nemetschek - SaaS momentum accelerates in Q1 2024

Waga Energy: Setting itself for profitable growth

Exclusive Networks: Q1 growth dampened by high comps as expected

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe